Available now: Building an Investable IP Portfolio Whitepaper
​

IPKat: Further analysis of Generics (t/a Mylan) v Yeda and Teva

No items found.
​
July 18, 2012
#
Litigation
#
Life
Table of contents
  • Toc Heading
  • Toc Heading

In addition to an earlier summary by Darren Smyth of the ruling in Generics (t/a Mylan) v Yeda and Teva, Darren has provided further analysis for the IPKat.

Darren's article looks at the issue of the interpretation and clarity of two features in the patent claims.

The case relates to a European patent owned by Yeda (for which Teva is exclusive licensee) for Teva’s glatiramer acetate product marketed under the trademark Copaxone.

Recent Case Reports

See all Case Reports

Orders to Produce Evidence at the UPC
19 August 2026
GC Aesthetics, Avient, IQIP and Dall Energy: four 2026 UPC rulings reveal how courts weigh proportionality, confidentiality and timing before ordering a party to produce evidence under Rule 190.
​
Replacement parts and the value of asserting a narrower claim combination
17 July 2026
The UPC's Düsseldorf Local Division found that Wessper's cartridges indirectly infringed Brita's patent, and that a narrower claim combination can turn a consumable into an essential element.
​
Late Applications for Provisional Measures Refused for Lack of Urgency
14 July 2026
In Ericsson v ASUSTeK, the Milan Local Division refused a provisional measures application filed 21 months into the case, finding continuing infringement and rising losses alone do not establish urgency.
​